Section Review: Retinoids: Biological Function and Use in the Treatment of Dermatological Diseases: Pulmonary-Allergy, Dermatological, Gastrointestinal & Arthritis

References

• PECK GL, DIGIOVANNA JJ: Synthetic retinoids in derma- •tology. In: The Retinoids (2nd edition). Sporn MB, RobertsAB, Goodman DS (Eds.). Raven Press Ltd., New York (1994):631-658. A comprehensive review of the field up to 1992.
   Google Scholar
• HONG WK, LORETTA MI: Retinoids and human cancer.
   Google Scholar
• ••In: The Retinoids (2nd edition). Spom MB, Roberts AB,Goodman DS (Eds.). Raven Press Ltd., New York (1994):597-630. A comprehensive review of the field up to 1993.
   Google Scholar
• ORFANOS CE, EHLERT R, GOLLNICK H: The retinoids. A review of their clinical pharmacology and therapeutic use. Drugs (1987) 34:459–503.
   Google Scholar
• SMITH MA, PARKINSON DR, CHESON BD, FRIEDMAN MA: Retinoids in cancer therapy. J. Ctn. Oncol. (1992) 10:839–864.
   PubMed Web of Science ®Google Scholar
• VOKES EE, WEICHSELBAUM RR, LIPPMAN SM, HONG WK:Head and neck cancer. New Engl. J. Med. (1993) 328:184–194.
   PubMed Web of Science ®Google Scholar
• LIPPMAN SM, KESSLER JF, MEYSKINS FL, Jr.: Retinoids aspreventive and theraupeutic anticancer agents (Part 1). Cancer Treatment Reports (1987) 71:391–405.
   Google Scholar
• SAURAT JH: Retinoids in dermatology. Rev. Prat. (1992)42:69–75.
   PubMedGoogle Scholar
• MANGELSDORF DJ, UMESONO K, EVANS RM: The retinoid ••receptor. In: The Retinoids. Academic Press, Orlando, Flor-ida (1994):319-349. A comprehensive review of the field up to 1992.
   Google Scholar
• LEID M KASTNER P, CHAMBON P: Multiplicity generates diversity in the retinoic add signalling pathways. Trends Bioc hem. Sci. (1992) 17:427–433.
   PubMed Web of Science ®Google Scholar
• HEYMAN RA, MANGELSDORF DF, DYCK JA, STEIN RB, EICHLE G, EVANS RM, THALLER C: 9-Cis retinoic add as a high affinity ligand for retinoid X receptors. Cell (1992) 68:397–406.
   Google Scholar
• LEVIN AA, STURZENBECICER LJ, KAZMAR S, BOSAKOWSKI T, HUSELTON C, ALLENBY G, SPECK J, ICRATZEISEN C, ROSENBERGER M, LOVEY A, GRIPPO JF: 9-Cis retinoic add stereoisomer binds and activates the nuclear re-ceptor RXlia. Nature (1992) 355:359-361. Demonstration of 9-cis RA as a ligand for RXRs.
   Google Scholar
• MANGELSDORF DJ, ONG ES, DYCK JA, EVANS RM: A nuclear receptor that identifies a novel retinoic add response pathway. Nature (1990) 345:224–229.
   PubMed Web of Science ®Google Scholar
• YU VC, DELSERT C, ANDERSON B, HOLLOWAY JM, DEVARY OV, NAAR AM, KIM SY, BOUTIN JM, GLASS CK, ROSENFELD MG: RXR-0: A coregulator that enhances binding of retinoic add, thyroid hormone and vitamin D receptors to their cognate response elements. Cell (1991) 67:1251–1266.
   PubMed Web of Science ®Google Scholar
• KLIEWER SA, UMESONO K, MANGELSDORF DJ, EVANS RM: Retinoid X receptor interacts with nuclear receptors in retinoic add, thyroid hormone and vitamin D3 signal-ling. Nature (1992) 355:446-449. Demonstration of heterodirnerisation of RXR with RAR, TR and VDR.
   Google Scholar
• MARKS MS, HALLENBECK PL, NAGATA T, SEGARS JH, APPELLA E, NIKODEM VM, OZATO K: 11-2R1U3P (RXR-13) heterodimerization provides a mechanism for combi-natorial diversity in the regulation of retinoic add and thyroid responsive genes. EMBO J. (1992) 11:1419–1435.
   PubMed Web of Science ®Google Scholar
• BUGGE TH, POHL J, LONNOY 0, STUNNENBERG HG: RXRa, a promiscuous partner of retinoic acid and thyroid hormone receptors. EMBOJ. (1992)11:1409–1418.
   PubMed Web of Science ®Google Scholar
• LEID M, KASTNER P, LYONS R, NAKSHATRI H, SAUNDERS M, ZACHAREWSKI T, CHEN JY, STAUB A, GARNIER JM, MADER S, CHAMBON P: Purification, cloning, and RXR identity of the HeLa cell factor with which RAR or TR heterodimerizes to bind target sequences efficiently. Cell (1992) 68:377-395. RXR heterodimerises with RAR and TR.
   Google Scholar
• KLIEWER SA, UMESONO K, NOONAN DJ, HEYMAN RA,EVANS RM: Convergence of 9-cis -rethwic add and per-oxisome proliferator signalling pathways through het-erodimer formation of their receptors. Nature (1992) 358:771–774.
   PubMed Web of Science ®Google Scholar
• ISSEMANN I, GREEN S: Activation of a member of thesteroid hormone receptor superfamily by peroxisome prolfferators. Nature (1990) 347:646-650. Demonstration of 9-cis RA as a ligand for RXRs.
   Google Scholar
• GOTTLICHER M, WIDMARK E, LI Q, GUSTAFSSON JA: Fattyadds activate a chimera of the clofibric acid activated Oa receptor and the glucocorticoid receptor. Proc. Natl. Acad. Sci. USA (1992) 89:4653–4657.
   PubMed Web of Science ®Google Scholar
• IBRAHIMI A, TEBOUL L, GAILLARD D, AMRI EZ, AILHAUD G, YOUNG P, CAWTHORNE MA, GRIMALDI PA: Evidence for a common mechanism of action for fatty adds and thiazolidinedione antidiabetic agents on gene expres-sion in preadipose cells. Mol. Pharm. (1994) 46:1070–1076.
   PubMed Web of Science ®Google Scholar
• KUROKAWA R, YU V, NAAR A, KYAKUMOTO S, HAN Z, SILVERMAN S, ROSENFELD MG, GLASS CK: Differential orientations of the DNA binding domain and carboxy-terminal dimerization interface regulate binding site selection by nuclear receptor heterodimers. Genes & Dev. (1993) 7:1423–1435.
   PubMed Web of Science ®Google Scholar
• KUROKAWA R, DIRENZO J, BOEHM M, SUGERMAN J, GLOSS B, ROSENFELD MG, HEYMAN RA, GLASS CK: Regu-lation of retinoid signalling by receptor polarity and allosteric control of ligand binding. Nature (1994) 371:528–531.
   PubMed Web of Science ®Google Scholar
• PERLMANN T, RANGARAJAN PN, UMESONO K, EVANS EM: Determinants for selective RAR and TR recognition of direct repeat HREs. Genes & Dev. (1993) 7:1411–1422.
   PubMed Web of Science ®Google Scholar
• NICHOLSON RC, MADER S, NAGPAL 5, LEID M, ROCHETTE- EGLY C, CHAMBON P: Negative regulation of the rat stromelysin gene promoter by retinoic acid is mediated by an AP1 binding site. EMBO J. (1990) 9:4443-4454. RARs antagonise API-dependent gene expression.
   Google Scholar
• SHULE R, RANGARAJAN P, YANG N, ICLEIWER S, RANSONE LJ, BOLADO J, VERMA IM, EVANS EM: Retinoic acid is a negative regulator of AP-1 responsive genes. Proc. Natl. Acad. Sci. USA (1991) 88:6092-6096. RAE antagonism of API-dependent genes.
   Google Scholar
• YANG-YEN H-F, ZHANG X-K, GRAUPNER G, TZUKERMAN M, SAKAMOTO B, KARIN M, PFAHL M: Antagonism be-tween retinoic add receptors and AP-1: Implications for tumor promotion and inflammation. New Biologist (1991) 3:1206-1210. RAE-AP1 antagonism.
   Google Scholar
• NAGPAL S, ATHANIKAR J, CHANDRARATNA RAS: Separa- don of transactivation and APi antagonism functions of retinoic acid receptor a. J. Biol. Chem. (1995) 270 :923-927. Pharmacological separation of transactivation of AP1-antagonism properties of RARs.
   Google Scholar
• FELLI MP, VACCA A, MECO D, SCREPANTI I, FARINA AR, MARODER M, MARTINO= S. PETRANGELI E, FRATI L, GULINO A: Retinoic acid-induced down-regulation of the interleukin-2 promoter via cis-regulatory se-quences containing an odamer motif. Mol. Cell. Biol. (1991) 11:4771–4778.
   Google Scholar
• ISHIDA S, SHUDO K, TAKADA S, KOIICE K: Transcription from the P2 promoter of human protooncogene myc is suppressed by retinoic acid through an interaction between the E2F element and its binding proteins. Cell Growth and Differentiation (1994) 5:287–294.
   PubMedGoogle Scholar
• CREEK fa, JENKINS GR, KHAN MA, BATO VA A, HODAM JR, TOLLESON WH, PIRISI L: Retinoic acid suppresses human papillomavirus type 16 (HPV16)-mediated transformation of human keratinocytes and inhibits the expression of the HPV16 oncogenes. In: Diet and Cancer: Markers, Prevention, and Treatment Plenum Press (1994) : 19–35.
   Google Scholar
• BARTSCH D, BOYE B, BAUST C, ZUR HAUSEN H, SCHWARZE: Retinoic acid-mediated repression of human papil- lomavirus 18 transcription and different ligand regu-lation of the retinoic acid receptor 13 gene in non-tu-morigenic and tumorigenic HeLa hybrid cells. EMBO J. (1992) 11:2283–2291.
   PubMed Web of Science ®Google Scholar
• WRIGHT JK, CLARK IM, CAWSTON TE, HAZLEMAN BL: Thesecretion of the tissue inhibitor of metalloproteinase (TIMP) by human synovial fibroblasts is modulated by all-trans-retinoic acid. Biochim. Biophys. Acta (1991) 1131(1):25–30.
   Google Scholar
• FANJUL A, DAWSON MI, HOBBS PD, JONG L, CAMERON JF, HARLEV E, GRAUPNER G, LU X-P, PFAHL M: A new class of retinoids with selective inhibition of AP-1 inhibits proliferation. Nature (1994) 372:107-111. Transcriptionally inert but AP1 selective retinoicis inhibit cell prolif-eration.
   Google Scholar
• ROSS AC, HAMMERLING UG: Retinoids and the immune ••system. In: The Retinoids: Biology, Chemistry, and Medicine.Raven Press Ltd. (1994):521-543. A comprehensive review of the field up to 1992.
   Google Scholar
• PASATTEMPO AMG, BOWMAN TA, TAYLOR CE, ROSS AC: Vitamin A depletion and repletion: Effects on antibody response to the capsular polysaccharide of Streptococ-cus pneuntrmtae, type M (SSS-M). Am.J. Clin. Nutr. (1989) 49:501–510.
   PubMedGoogle Scholar
• SEMBA RD, MUHILAL SAL, NATADISASTRA G, WIRASAS-MITA S, MEIF L, RIDWANE, WEST KP, SOMMER A: De-pressed immune response to tetanus in children with vitamin A deficiency. J. Nutr. (1992) 122:101–107.
   PubMed Web of Science ®Google Scholar
• PARENT G, ROUSSEAUX-REVOST R, CARLIER Y, CAPRON A: Influence of vitamin A on the immune response of Scbistosoma mansoni-infected rats. Trans R. Soc. Trop. Med. Hyg. (1984) 78:380–384.
   PubMed Web of Science ®Google Scholar
• TOKUYAMA H, TOKUYAMA Y: Retinoids enhance IgA production by lipopolysaccharide-stimulated murine spleen cells. Cell. Immun. (1993) 150:353–363.
   PubMed Web of Science ®Google Scholar
• SIJTSMA SR, ROMBOUT JH, WEST CE, VAN DER ZIJPP AJ: Vitamin A deficiency impairs cytotoxic T-lymphocyte activity in Newcastle disease virus-infected chickens. Vet. Immunol. Immunopathol. (1990) 26:191–201.
   PubMed Web of Science ®Google Scholar
• BUTERA ST, KRAKOWICA S: Assessment of lymphocyte function during vitamin A deficiency. Am. J. Vet. Res. (1986) 47:850–855.
   PubMed Web of Science ®Google Scholar
• NAUSS KM: Influence of vitamin A status on the immunesystem. Im Vitamin A deficiency and its control. Academic Press (1986):207–243.
   Google Scholar
• MARK DA, NAUSS KM, BALIGA BS, SUSICIND EM: De-pressed transformation response by splenic lympho-cytes from vitamin A-deficient rats. Nutr. Res. (1981) 1:89–497.
   Google Scholar
• BUCK J, RITTER G, DANNECKER L, KATFA V, COHEN SL,CHAIT BT, HAMMERLING U: Retinol is essential for growth of activated human B-cells. I Exp. Med. (1990) 171:1613–1624.
   PubMed Web of Science ®Google Scholar
• BUCK J, DERGUINI F, LEVI E, NAKANISHI K, HAMMERLING U: Intracelhilar signalling by 14-hydroxy-4, 14-retro-retinoL Science (1991) 254:1654-1656. A metabolite of retinol required for B-cell growth.
   Google Scholar
• SIDELL N, CHANG B, BHATTI L: Upregulation by retinoic add of interleukin-2-receptor rnRNA in human T-lym-phocytes. Cell. Immunol. (1993) 146:28–37.
   PubMedGoogle Scholar
• AOUDJIT F, BOSSE M, STRATOWA C, VORABERGER G, AUDETTE M: Regulation of intercellular adhesion mole-cule-1 expression by retinoic acid: analysis of the 5' regulatory region of the gene. Int. J. Cancer (1994) 58:543–549.
   PubMed Web of Science ®Google Scholar
• BRINC10ERHOFF CE, COFFEY JW, SULLIVAN AC: Inflam- emation and collagenase production in rats with adju-vant arthritis reduced with 13-cis retinoic add. Science (1983) 221:756-758. Anti-inflammatory action of 13-cis RA in an animal model.
   Google Scholar
• ALEXANDER CM, WERB Z: Proteinases and extracellular matrix remodeling. Curr. Opin. Cell. Biol. (1989) 1:974–982.
   PubMed Web of Science ®Google Scholar
• SAXON A, KELD B, BRAUN J, BOTDSON A, SIDELL N: Long-term administration of 13-cis retinoic acid in common variable immunodeficiency circulating inter-leukin-6 levels, B-cell surface molecule display, and in vitro and in vivo B-cell antibody production. Immunol-ogy (1993) 80:477487.
   Google Scholar
• MITSUYASU RT: Clinie21 aspects of AIDS-related Kaposi's sarcoma. Curr. Opin. Oncol. (1993) 5:835–844.
   PubMedGoogle Scholar
• KISHIMOTO T, AICIRA S, TAGA T: Interleukin-6 and its receptor A paradigm for cytokhies. Science (1992) 258:593–597.
   PubMed Web of Science ®Google Scholar
• MEHTA K, MCQUEEN T, TUCKER S, PANDITA R, AGGAR-WAL BB: Inhibition by all-trans-retinoic add of tumor necrosis factor and nitric oxide production by perito-neal macrophages. J. Leukoc. Biol. (1994) 55:336–342.
   PubMed Web of Science ®Google Scholar
• BECHEREL P-A, MOSSALAYI MD, LE GOFF L, FRANCES C, CHOSIDOW 0, DEBRE P, AROCK M: Mechanisms of anti-inflammatory action of retinoids on keratinocytes. The Lancet (1994) 344:1570–1571.
   PubMedGoogle Scholar
• HANAZAWA S, TAKESHITA A, KITANO S: Retinoic acid suppression of c-fos gene inhibits expresssion of tu-mour necrosis factor-a-induced monocyte chemoat-tractantJE/MCP-1 in ckmalosteoblastic MC3T3-E1 cells. J. Biol. Chem. (1994) 269:21379–21384.
   PubMedGoogle Scholar
• NORRIS DA, OSBORN R, ROBINSON W, TONNESEN G: Isotretinoin produces significant inhibition of mono-cyte and neutrophil chemotaxis in vivo in patients with cystic acne. J. Invest. Dermatol. (1987) 89:38–43.
   PubMed Web of Science ®Google Scholar
• KOLB-BACHOFEN V, FEHSEL K, MICHEL G, RUZICKA T: Epidermal keratinocyte expression of indudble nitric oxide synthase in skin lesions of psoriasis vulgar's. The Lancet (1994) 344:139.
   PubMed Web of Science ®Google Scholar
• ESGLEYES- RIBOT T, CHANDRARATNA RA, LEW-KAYA DA, SEFTON J, DUVIC M: Response of psoriasis to a new topical retinoid, AGN 19190168. J. Am. Acad. Dermatol. (1994) 30:581-590. A clinical trial demonstrating the efficacy of an RAROPy selective retinoid for the treatment of psoriasis.
   Google Scholar
• NAGPAL S, PATEL S, FRIANT S, SHAFER J, ASANO AT, TENG M, THACHER S, DUVIC M, CHANDRARATNA RAS: Negative regulation of psoriasis associated markers MRP-8 and SKALP by retinoids. Submitted.
   Google Scholar
• LACKMANN M, RAJASEICARIAH P, IISMAA SE, JONES G, CORNISH CJ, HU S, SIMPSON RJ, MORITZ RL, GECZY CL: Identification of a chemotactic domain of the pro-in-flammatory S100 protein CP-10. J. Immunol. (1993) 150:2981–2991.
   PubMed Web of Science ®Google Scholar
• ODINK K, CERLETTI N, BRUGGEN J, CLERC RG, TARCSAY L, ZWALDO G, GERHARDS G, SHLEGEL R, SORG C: Two calcium binding proteins in infiltrate macrophages of rheumatoid arthritis. Nature (1987) 330:80–82.
   PubMed Web of Science ®Google Scholar
• MADSEN P, RASMUSSEN HH, LEFFERS H, HONORE B, DEFGAARD K, OLSEN E, MIL J, WALBUM E, ANDERSON AH, BASSE B, LAURIDSEN JB, RATZ GP, CELIS A, VANDEK-ERCKHOVE J, CELIS JE: Molecular cloning, occurrence, and expression of a novel partially secreted protein `psoriashf that is highly up-regulated in psoriatic skin. J. Invest. Dermatol (1991) 97:701–712.
   PubMed Web of Science ®Google Scholar
• BARTHE C, FIGARELLA C, CARRERE J, GUY-CROTTE 0: Identification of 'cystic fibrosis protein' as a complex of two calcium-binding proteins present in human cells of myeloid origin. Biochim. Biophys. Acta. (1991) 1096:175–177.
   PubMed Web of Science ®Google Scholar
• HESSIAN PA, EDGEWORTH J, HOGG N: MRP-8 and MRP-14, two abundant Ca2+-binding proteins of neutrophils and monocytes. j Leukoc. Biol. (1993) 53:197–204.
   PubMed Web of Science ®Google Scholar
• BREATHNACH SM: The skin immune system and psoria-sis. Clin. Exp. Immunol (1993) 91:343–345.
   PubMed Web of Science ®Google Scholar
• YANG Y, VACCHIO MS, ASH WELL JD: 9-Cis retinoic add inhibits activation-driven T-cellapoptosis: Implications for retinoid X receptor involvement in thymocyte de- velopment. Proc. Natl. Acad. Sci. USA. (1993) 90:6170-6174. Inhibition of activation induced programmed cell death in T-cells by 9-cis RA.
   Google Scholar
• DELIA D, AIELLO A, LOMBARDI L, PELICCI PG, GRIGNANI F, FORMELLI F MENARD S, COSTA A, VERNOSI U, PIERO= MA: N-(4-Hydroxyphenypretinamide induces apop-tosis of malignant hemopoietic cell lines including those unresponsive to retinoic acid. Cancer Research (1993) 53:6036–6041.
   PubMed Web of Science ®Google Scholar
• BIRO DE, SHALITA AR: Clinical aspects of topical reti-noids. Skin Pharmacol (1993) 6\(Suppl. 1):24–34.
   Google Scholar
• SHAHIDULLAH M, THAM SN, GOH CL: Isotretinoin ther-apy in acne vulgaris: a 10-year retrospective study in Singapore. Int. J. Dermatol. (1994) 33:60–63
   PubMed Web of Science ®Google Scholar
• GERSTE1t H: Anticarcinogenic effects of common carote-noids. Internat. J. Vit. Nutr. Res. (1993) 63:93–121.
   PubMedGoogle Scholar
• CRAEMER ICH, DIGIOVANNA JJ, MOSHELL AN, TARONE RE,PECK GL: Prevention of skin cancer in xeroderma pigmentosum with use of oral istretinoin. New Engl. J. Med. (1988) 318:1633–1637.
   Google Scholar
• ICRAEMER KH, DIGIOVANNA JJ, MOSHELL AN, TARONE RE, PECK GL: Oral isotretinoin prevention of skin cancer in xeodenna pigmentosum: individual variation in dose response. J. Invest. Dermatol. (1990) 94:544.
   Web of Science ®Google Scholar
• FISHER GJ, TALWAR ITS, MAO J-H, DATER SC, REDDY AP, GAUB M-P, ROCHE111.-EGLY C, CHAMBON P. VOORHEES JJ: Immunological identification and functional quanti-tation of retinoic add and retinoid X receptor proteins In human skin. J. Biol. Chem. (1994) 269(32):20629–20635. Quantitation of RARs and RXRs in human skin.
   Google Scholar
• CONNOR MJ, ASHTON RE, LOWE NJ: A comparitive study of the induction of epidermal hyperplasia by natural and synthetic retinoids. J. Pharmacol. Exp. Ther. (1986) 237:31–35
   PubMed Web of Science ®Google Scholar
• VARANI J, NICKOLOFF BJ, DIX1T VM, MITRA RS, VOOR-HEES JJ: All-trans retinoic add stimulates growth of aduh human keratinocytes cuhured in growth factor-deficient medium, inhibits production of throm-bospondln and fibronectin, and reduces adhesion. J. Invest. Dermatol. (1989) 93:449–454.
   PubMed Web of Science ®Google Scholar
• TONG PS, HOROWITZ NN, WHEELER LA: Trans retinoic add enhances the growth response of epidermal kerat-inocytes to epidermal growth factor and transforming growth factor beta. J. Invest Dermatol. (1990) 94:126–131.
   PubMed Web of Science ®Google Scholar
• REGNIER M, EUSTACHE J, SHROOT B, DAMON M: Bioas-says for retinoic add-like substances using cultured human keratinocytes. Skin Pharmacol. (1989)2:1–9.
   PubMedGoogle Scholar
• SAUNDERS NA, BERNACKI SH, VOLLBERG TM, .1E11 EN AM: Regulation of tranaglutaminase Type 1 expression in squamous differentiating rabbit tracheal epithelial cells and human epidermal keratinocytes: effects of retinoic acid and phorbol ester. Mol. Endocrinot (1993) 7:387–398.
   Google Scholar
• SAUNDERS NA, JETTEN AM: Control of growth regulatory and diferentiation-specific genes in human epidermal keratinocytes by interferon y. J. Biol. Chem. (1993) 269(3):2016–2022.
   Web of Science ®Google Scholar
• ASSELINEAU D, BERNARD BA, BALLLY C, DARMON M: Retinoic add improves epidermal morphogenesis. Dev. Biol. (1989) 133:322–335.
   PubMed Web of Science ®Google Scholar
• ASSELINEAU D, DALE BA, BERNARD BA: Filaggrin produc-tion by cultured human epidermal keratinocytes and Its regulation by retinoic add. Differentiation (1990) 45:221–229.
   PubMed Web of Science ®Google Scholar
• KOPAN R, TRASKA G, FUCHS E: Retinoids as important regulators of terminal differentiation: Examining kera-tin expression in individual epidermal cells at various stages of keratinisation. J. Cell. Biol. (1987) 105:427–440.
   PubMed Web of Science ®Google Scholar
• BROWN LJ, GEESIN JC, ROTHNAGEL JA, ROOP DR, GOR-DON JS: Retinoic add suppression of loriain expres-sion in reconstituted human skin cultured at the liquid-air interface. J Invest. Dermatol. (1994) 102:886–890.
   PubMed Web of Science ®Google Scholar
• MAGNALDO T, BERNERD F, ASSELINEAU D, DARMON M: Expression of lorictin in negatively controlled by reti-noic acid in human epidermis reconstructed in vitro. Differentiation (1992) 49:39–46.
   PubMed Web of Science ®Google Scholar
• BERNARD BA: Adapalene, a new chemical entity with retinoid activity. Skin Pharrnacol (1993) 6\(Suppl. 1):61–69. A review describing pre-clinical pharmacology of aclapalene.
   Google Scholar
• CHANDRARATNA R, PATEL S, DUVIC M, NAGPAL S: Sub-tractive hybridisation cloning of a candidate marker gene from skin raft cultures, reveals the anti-inflamma-tory action of retinoids. J. Invest. Dermatol.(1994) 102:625.
   Web of Science ®Google Scholar
• GRIFFITHS EM, ELDER fr, BERNARD BA, ROSSIO P, CRO-MIE MA, FINKEL LJ, SHROOT B, VOORHEES B: Com-parision of CD271 (Adapalene) and all-trans retinoic acid in human skin: Dissociation of epidermal effects and CRABP-II mRNA expression. J Invest. Dermatol. (1993) 101325–328.
   Google Scholar
• ELDER fr, CROMIE MA, GRIFFITHS CEM, CHAMBON P, VOORHEES B: Stimulus-selective induction of CRAIIP-II mRNA: A marker for retinoid add action in human skin. J. Invest. Dermatol. (1993) 100:356–359.
   PubMed Web of Science ®Google Scholar
• ELDER JT, CROMIE MA: Retinoid regulation of CRABP-II mRNA in an organotypic keratinocyte culture system. J. Toxicol.-Cut. & Ocular Toxicol. (1993) 12(2):173–181.
   Web of Science ®Google Scholar
• GRIFFITHS CEM, RUSSMAN AN, MAJMUDAR G, SINGER RS, HAMILTON TA, VOORHEES B: Restoration of collagen formation in photodamaged human skin by tretinoin (retinoic acid). New Engl. J. Med. (1993) 329:530–535.
   PubMed Web of Science ®Google Scholar
• ABERGEL RP, MEEKER CA, OIKARINEN H, OIKARINEN Al,UITTO J: Retinoid modulation of connective tissue me- tabolism in keloid fibroblast cultures. Arch. Dermatol. (1985) 121:632–635.
   PubMed Web of Science ®Google Scholar
• ZHOU L, OTULAKOWSKI G, PANG J, MUNROE DG, CAPE-TOLA RJ, LAU C: Quantitation of human cellular retinoic add-binding protein II (CRA13P-11) RNA from cultured human skin fibroblast cells and human skin biopsies treated with retinoic acid. Nue . Acids. Res. (1992) 20(23):6215–6220.
   PubMed Web of Science ®Google Scholar
• LARSEN FG, VOORHEES JJ, ASTROM A: Retinoic acid induces expression of early growth response gene-1 (Egr-1) in human skin in vivo and in cultured skin fibroblasts. J. Invest. Dermatol. (1994) 102:730–733.
   PubMed Web of Science ®Google Scholar
• LANDTHALLER M, KUMMERMEHR J, WAGNER A, PLEWIG G: Inhibitory effects of 13-cis-retinoic acid on human sebaceous glands. Arch. DermatoL Res. (1980) 269:297–309.
   PubMed Web of Science ®Google Scholar
• PECK GL, OLSEN TG, YODER FW, STRAUSS JS, DOWNING DT, PANDYA M, BUTKUS D, ARNAUD-BATTANDIER J: Prolonged remissions of cystic and conglobate acne with 13-cis-retinoic acid. New Engl.J. Med. (1979) 300:329–333.
   PubMed Web of Science ®Google Scholar
• STRAUSS JS, STRANIERI AM, FARRELL LN, DOWNING DT: The effect of marked inhibition of sebum production with 13-cis-retinoic acid on skin surface lipid composi-tion. J. Invest. Dermatol. (1980) 74:66–67.
   PubMed Web of Science ®Google Scholar
• DORAN TI, SHAPIRO SS: Retinoid effects on sebocyte proliferation. Methods Enzymot. (1990) 190:334–338.
   PubMed Web of Science ®Google Scholar
• SHAPIRO SS, HURLEY J: Effect of retinoid on sebaceous glands. Methods Enzymot (1990) 190:326–333.
   PubMed Web of Science ®Google Scholar
• ZOUBOULIS CC, KORGE B, AKAMATSU H, XIA LQ, SCHILLER S, GOLLNICK H, ORFANOS CE: Effects of 13-cis-retinoic acid, all-trans-retinoic add, and acitretin on the proliferation, lipid synthesis and keratin expres-sion of cultured human sebocytes in vitro. J. Invest. Dermatol. (1991) 96:792–797.
   PubMed Web of Science ®Google Scholar
• RAFAL ES, GRIFFITHS CEM, DITRE CM, FINKEL LJ, HAMIL-TON TA, ELIIS CN, VOORHEES JJ: Topical tretinoin (ret-inoic add) treatment for liver spots associated with photodamage. New Engl. J. Med. (1992) 326:368–374.
   PubMed Web of Science ®Google Scholar
• NAIR X, TRAMPOSCH KM: UVB-induced pigmentation in hairless mice as an in vivo assay for topical skin-depig-menting activity. Skin. Phannacol. (1989) 2:187–197.
   PubMedGoogle Scholar
• HOAL E, WILSON EL, DOWDLE EB: Variable effects of retinoids on two pigmenting human melanoma cell lines. Cancer Res. (1982) 42:5191–5195.
   PubMed Web of Science ®Google Scholar
• HOSOI J, ABE E, SUDA T, ICUROK1 T: Regulation of melanin synthesis of 1116 mouse melanoma cells by la,25-dihydrox-yvitamin D3 and retinoic add. Cancer Res. (1985) 45:1474–1478.
   PubMed Web of Science ®Google Scholar
• EDWARD M, GOLD JA, MACKIE RM: Different suscepti-bilities of melanoma cells to retinoic acid-induced changes in melanomic expression. Biochem. Biophys. Res. Commun. (1988) 155:773–778.
   PubMed Web of Science ®Google Scholar
• ORLOW SJ, CHAKRABORTY AK, PAWELEK JM: Retinoic add is a potent inhibitor of indudble pigmentation in murine and hamster melanoma cell lines. J. Invest. Dermatol. (1990) 94:461–464.
   PubMed Web of Science ®Google Scholar
• STIM TB, FLINT LE, GENDIMENICO GJ, CAPETOLA RJ, MEZICK JA: Retinoid inhibition of induced pigmenta-tion in Cloudman S91 murine melanoma cells. J. Invest. Dermatol. (1992) 98:646
   Web of Science ®Google Scholar
• AUVINEN M, PAASINEN A, ANDERSSON LC, HOLTTA E: Ornithine decarboxylase activity is critical for cell transformation. Nature (1992) 360:355–358.
   PubMed Web of Science ®Google Scholar
• TABOR CN, TABOR H: Polymines. Ann. Rev. Biocbem. (1984) 53:749–790.
   PubMed Web of Science ®Google Scholar
• VERMA AK, BOUTWELL RK: Vitamin A acid (retinoic acid), a potent inhibitor of 12-o-tetradecanoylphorbol-13-acetate-induced ornithine decarboxylase activity in mouse epidermis. Cancer Res. (1977) 37:2196–2201
   PubMed Web of Science ®Google Scholar
• MAO Y, GURR JA, HICKOK NJ: Retinoic acid regulates ornithine decarboxylase gene expression at the tran-scriptional level. Biochem. J. (1993) 295:641–644.
   PubMed Web of Science ®Google Scholar
• BRASELMANN S, BERGERS G, WRIGHTON C, GRANINGER P, SUPERTI-FURGA G, BUSSLINGER M: Identification of fos target genes by the use of selective induction sys-tems. J. Cell. Sci. (1992) 16(Suppl.):97–109.
   Google Scholar
• DE LUCA LM, SLY L, JONES CS, CHEN L-C: Effects of dietary retinoic acid on skin papilloma and cardnoma forma-tion in female SENCAR mice. Carcinogenesis (1993) 14(3):539–542.
   PubMed Web of Science ®Google Scholar
• VERMA AK, SHAPAS BG, RICE BM, BOUTWELL RK: Corre-lation of the inhibition by retinoids of tumour pro-moter-induced mouse epidermal ornithine decarboxylase activity and of skin tumour promotion. Cancer Res. (1979) 39:419–425.
   PubMed Web of Science ®Google Scholar
• MCCORMICK D. MOON RC: Antipromotional activity of dietary N-(4-hydroxyphenyHretinamide in two-stage skin tumourigenesis in CD-1 and Sencar mice. Cancer Lett. (1986) 31:133–138.
   PubMed Web of Science ®Google Scholar
• MCMORMICK DL, BAGG BJ, HULTIN TA: Comparative activity of dietary or topical exposure to three retinoids in the promotion of skin tumour induction in mice. Cancer Res. (1987) 47:5859–5993.
   Google Scholar
• BOUTWELL RK: The role of the induction of ornithine decarboxylase in tumour promotion. In: Origins of hu-man cancer (Book B). Cold Spring Harbor Lab. (1977):773–783.
   Google Scholar
• VERMA AK: Modulation of carcinogenesis by vitamin A and its analogs (retinoids). In: Vitamins and cancer prevention. Wiley-Liss (1991):25–37.
   Google Scholar
• MEZICK JA, BHATIA MC, CAPETOLA RJ: Topical and sys-temic effects of retinoids on horn-filled utriculus size in the rhino mouse. A model to quantify 'antikeratinis-ing' effects of retinoids. J. Invest. Dermatol. (1984) 83:110–113.
   PubMed Web of Science ®Google Scholar
• ZHENG P, GENDIMENICO GJ, MEZICK JA, KLINGMAN AM: Topical all-trans retinoic acid rapidly corrects the fol-licular abnormalities of the rhino mouse. Acta Derm. Venereol. (1993) 73:97–101.
   PubMed Web of Science ®Google Scholar
• BERNARD F, DEMARCHEZ M, ORTONNE J-P, CZERNIELEWSKI J: Sequence of morphological events during topical application of retinoic add on rhino mouse skin. Br. J. Dermatol. (1991) 125:419–425.
   PubMed Web of Science ®Google Scholar
• KLINGMAN LH, KLINGMAN AM: The effect on rhino mouse skin of agents which influence keratinisation and exfoliation. J. Invest. Dermatol. (1979) 73:354–358.
   PubMed Web of Science ®Google Scholar
• CHATELUS A, CARRON JC, SHROOT B, EUSTACHE J, HEN-SBY CN: Structure activity relationships between differ-ent retinoids using the topical rhino mouse comedolytic modeL In: Pharmacology of retinoids In the skin. Karger, Basel. Pharmacol Skin (1989) 3:144–148.
   Google Scholar
• BORIS A, HURLEY J, WONG CQ, COMAI K, SHAPIRO S: Sebum-suppressing activity of the nonpolar arotinoid Ro 13-0778 in rodents. Arch. Dermatol. Res. (1988) 280246–251.
   Google Scholar
• SHAPIRO SS, HURLEY J: Effect of retinoids on sebaceous glands. Methods Enzymol. (1990) 190326–333.
   Google Scholar
• GOMEZ EC: Differential effect of 13-cis-retinoic add and an aromatic retinoid (Ro 10-9359) on the sebaceous glands of the hamster flank organ. J. Invest. Dermatol. (1981) 7568–69.
   Google Scholar
• PLEWIG G, LUDERSCHMIDT C: Hamster ear model for sebaceous glands. j. Invest. Dermatol. (1977) 68:171–176.
   PubMed Web of Science ®Google Scholar
• BIRO DE, SHALITA AR: Clinit-21 aspects of topical reti-noids. Skin PharmacoL (1993) 6(Suppl.):53–60.
   Google Scholar
• WEISS JS, ELLIS CN, HEADINGTON JT, VOORHEES JJ: Topical tretinoin in the treatment of aging skin. J. Am. Acad. Dermatol. (1988) 19169–175.
   Google Scholar
• WEINSTEIN GD, NIGRA TP, POCHI PE, SAWN RC: Topical tretinoin for the treatment of photodamaged skin. Arch. Dermatol. (1991) 127:659–665.
   PubMed Web of Science ®Google Scholar
• ARMSTRONG RB, LESIEWICZ J, HARVEY G, IRE LF: Clinical panel assessment of photodamaged skin treated with isotretinoin using photographs. Arch. Dermatot (1992) 128352–356.
   Google Scholar
• KIMBROUGH GCK, GRIFFITHS CE, FINICEL LJ, HAMILTON TA, BULENGO RSM, ELLIS CN, VOORHEES JJ: Topical retinoic add (Tretinoin) for melasma in black patients. A vehicle-controlled clinical trial. Arch. Dermatol. (1994) 130:727–733.
   PubMedGoogle Scholar
• BULENGO-RANSBY SM, GRIFFITHS CEM, ICIMBROUGH-GREEN CK, FINKEL LJ, HAMILTON TA, ELLIS CN, VOOR-HEES JJ: Topical tretinoin (retinok add) therapy for hyperpigmented lesions caused by infl2mination of the skin in black patients. New Engl. J. Med. (1993) 328:1438–1443.
   PubMed Web of Science ®Google Scholar
• STEIJLEN PM, RELFENSCHWEILER DOH, RAMAEICERS FCS, VAN MUIJEN GNP, HAPPLE R, LINK M, RUTTER DJ, VAN DE ICERKHOF PCM: Topical treatment of ichthyoses and Darier's disease with 13-cis-retinoic add. Arch. Derma-tol. Res. (1993) 285:221–226.
   PubMed Web of Science ®Google Scholar
• LIPPMAN SM, MEYSKENS FL JR: Treatment of advanced squamo us cell carcinoma of the skin with isotretinoin. Ann. Intern. Med. (1987) 107:499–501.
   PubMed Web of Science ®Google Scholar
• LIPPMAN S, PARKINSON DR, ITRI LM, WEBER RS, SCHANTZ SP, OTA DM, SCHUSTERMAN MA, KRAKOFF 111, GUTTER-MAN JU, HONG WK: 13-as-retinoic acid and interferon-alpha-2a. Effective combination therapy for advanced squamous cell carcinoma of the skin./ Natl. Cancer Inst. (1992) 84:235-240. Clinical efficacy of retinoid and INF-a combination therapy in SCC.
   Google Scholar
• PECK G, DIGIOVANNA JJ, SARNOFF DS, GROSS EG, BUT-KUS D, OLSEN TG, YODER FW: Treatment and preven-tion of basal cell carcinoma with oral isotretinoin. J. Am. Acad. Dermatol. (1988) 19:176–185.
   PubMed Web of Science ®Google Scholar
• TOMA A, VINCENTI M, PALUMBO R, MUZIO G, RAINER° ML, SANTI P, ROSSO R: Results of the assodation of intralesional recombinant alpha interferon-2a (aIFN) plus 13-cis-retinoic add (13cRA) in the treatment of basal cell carcinomas (BCC) of the skin. Int. J. Oncol. (1993) 3:1149–1154.
   PubMed Web of Science ®Google Scholar
• KESSLER JF, JONES SE, LEVINE N, LYNCH PJ, ROHMAN BOOTH A, MEYSKENS FL: Isotretinoin and cutaneous helper T-cell lymphoma (mycosis fungoides). Arch Der-matol. (1987) 123:201–214.
   Google Scholar
• HOTTNG E, MEISSNER K: Arotinoid-Ethylester: Effective-ness in refractory cutaneous T-cell lymphoma. Cancer (1988) 62:1044–1048.
   PubMed Web of Science ®Google Scholar
• TOUSIGNANT J, RAYMOND GP, LIGHT MJ: Treatment of cutaneous T-cell lymphoma with the arotinoid Ro 13-629&j. Am. Acad. Dermatol. (1987) 16:167–171.
   PubMed Web of Science ®Google Scholar
• MOLIN L, THOMSEN K, VOLDEN G, ARONSSON A, HAM-MAR H, HELLBE L, WANTZINI GL, ROUPE G: Oral retinoids In mycosis fungoides and Sezary syndrome: a compari-son of isotretinoin and etretinate. A study from the Scandinavian Mycosis Fungokles Group. Acta. Derm. Venereol. (1987) 67:232–236.
   PubMed Web of Science ®Google Scholar
• ZACHARIAE H, THESTRUP-PEDERSEN K: Interferon alpha and etretlnate combination treatment of cutaneous T-cell lymphoma. J. Invest. DermatoL (1990) 95:206S–208S.
   Google Scholar
• MAHRLE G, THEILE B: Retinoids in cutaneous T-cell lymphomas. Dermatoligica (1987) 175:145S–150S.
   Google Scholar
• MASOOD R, CAI J, LAW R, GILL P: AIDS-associated Kaposrs sarcoma pathogenesis, Clinical features, and treatment. Curr. Opin. Oncol. (1993) 5:831–834.
   PubMedGoogle Scholar
• BONHOMME L, FREDJ G, GROSSIORD J-L, SZEICELY AM, DULEBA B, RATINEY R, AVEROUS S, MISSET J-L, JASMIN C: Formulation of all trans retinoic add gel for topical treatment of epidemic Kaposi sarcoma lesions. J. Pharm. din. (1993) 12:77-80. A small clinical trial showing the efficacy of RA in KS.
   Google Scholar
• SHARPE RJ, KADIN ME, HARMON DC, IMBER MJ, ANDER-SON RR: Complete resolution of Kaposrs sarcoma with systemic etretinate therapy in a patient with mycosis fungoides. J. Am. Acad. Dermatol. (1989) 20(6):1123–1124.
   PubMed Web of Science ®Google Scholar
• ZIEGLER JL, VOLBERDING PA, ITRI LM: Failure of isotret-inoin in Kaposrs sarcoma. Lancet (1984) 2(8403):641.
   PubMedGoogle Scholar
• MITSUYASU RT: Clinical aspects of AIDS-related Kaposr s sarcoma. Curr. Opin. Oncot (1993) 5:835–844.
   PubMedGoogle Scholar
• MILLS CM, MARKS R: Adverse reactions to oral retinoids. An update. Drug Sal (1993) 9:280–290.
   PubMed Web of Science ®Google Scholar
• DAVID M, HODAK E, LOWE NJ: Adverse effects of reti-noids. Med. Toxicol. Adverse Drug Exp. (1988) 3:273–288.
   PubMedGoogle Scholar
• GROSS EG, HELFGOTT MA: Retinoids and the eye. Der-matol. Clin. (1992) 10:521–531.
   Google Scholar
• KISTLER A, TSUCHIYA T, TSUCHIYA M, KLAUSI M: Terato-genicity of arotinoids (retinoids) in vivo and in vitro. Arch. Toxicol. (1990) 64:616–622.
   PubMed Web of Science ®Google Scholar
• SHALITA AR: Lipid and teratogenic effects of retinoids J. Am. Acad. Dermatol. (1988) 19:197–198.
   PubMed Web of Science ®Google Scholar
• NIICIFORIDIS G, TSAMBAOS D, KARAMITSOS, D, KOUTS0-JANNIS C, GEORGIOUS S: Effects of oral isotretinoin on human auditory brainstem response. Dermatology (1994) 189:62–64.
   Google Scholar
• YOB EH, POCHI PE: side-effects and long term toxicity of synthetic retinoids. Arch. Dermatol. (1987) 123:1375–1378.
   PubMed Web of Science ®Google Scholar
• WARRELL RP: Retinoid resistance in acute promyelocytic leukemia: New mechanisms, strategies and implica-tions. Blood (1993) 82:1949–1953.
   PubMed Web of Science ®Google Scholar
• HENSBY C, CAVAY D, BOUCIIER M, CHATELUS A, ALGATE D, EUSTACHE J, SHROOT B: The in vivo and in vitro anti-inflammatory activity of CD271: A new retinoid-like modulator of cell differentiation. Agents Actions (1990) 29:56–58.
   PubMedGoogle Scholar
• VERSHOORE M, L;ANGNER A, WOLSKA H, JABLONSKA 5, CZERNEELEWSKI J, SCHAEFER H: Efficacy and safety of topical CD271 alcoholic gels. Anew treatment candidate for acne vulgaris. Br. J. Dermatol. (1990) 124:368–371.
   Google Scholar
• BERNARD BA, BERNARDON JM, DEE FSCLUSE C, MARTIN B, CHARPENTIER B, PILGRIM WR, REICHERT U, SHROOT B: Identification of synthetic retinoids with selectivity for human nuclear synthetic retinoic acid receptor y. Biochem. Biophys. Res. Commun. (1992) 186:977–983.
   PubMed Web of Science ®Google Scholar
• BERNARD F, ORTONNE JP, BOUCLIER M, CHATELUS A, HEMSBY C: The rhino mouse model: The effects of topically applied all-trans retinoic acid and CD271 on the fine structure of the epidermis and utride wall of pseudocomedones. Arch. Dermatol. Res. (1991) 283:100–107.
   PubMed Web of Science ®Google Scholar
• JAMOULLE JC, GRANDJEAN L, LAMAUDE E, SHROOT B, SCHAEFER H: Follicular penetration and distribution of topically aplied CD271, a new naphthoic acid derivative intended for topical acne treatment. J. Invest. Dermatol. (1990) 94:731–732.
   PubMed Web of Science ®Google Scholar
• CUNLIFFE WJ, ORFANOS C, CAPUTO R, FORATROM L, HENNEN M, PRIVAT Y, DRENA B, ANGILAR AR, CZERNEILEWSKI J, PONCETM, VERSCHOORE M: Compari-son of Clinical safety and efficacy of adapakne gel and retin-A gel in the treatment of acne vulgaris. Procedings of the 53rd annual meeting of the American Association of Dermatology (1995):195.
   Google Scholar
• WEINSTEIN G, JEFES E, DUVIC M, FREEDMAN D, JEGA-SOTHY B, THARP M, JORIZZO J, KRUEGER G, LOWE N, SHMUNES E, TSCHEN E, MONROE A, SEFTON J, LEW-KAYA D, LUE J, CHANDRARATNA R, GIBSON J: Tazarotene gel for the treatment of plague psoriasis: a double-blind clin3c2l study. J. Invest. Dermatol. (1995) 104:661.
   Web of Science ®Google Scholar
• HSYU PH, BOWEN B, TANG-LIU D: Pharmacokinetics of a novel retinoid AGN 190168 and its metabolite AGN 190299 after intravenous administration of AGN 190168 to rats. Biopharm. Drug Dispos. (1994) 15:347–357.
   PubMed Web of Science ®Google Scholar
• LIU SS, SANDRI RB, TANG-LIU DDS: Systemic pharmaco-kinetics of acetylenic retinoids in rats. Drug Metab. Dispos. (1990) 18:1071–1077.
   PubMed Web of Science ®Google Scholar
• CHIEN DS, SANDRI RB, TANG-LUI DDS: Systemic pbarma-cokinetics of Acitretin, Etretinate, Isotretinoin, and acetylenic retinoids in guinea pigs and obese rats. Drug Metab. Dispos. (1992) 20:211–217.
   PubMed Web of Science ®Google Scholar
• BOEHM MF, MCCLURG MM, PATHIRANA C, MAN-GELSDORF D, WHITE SK, HERBERT J, WINN D, GOLDMAN ME, HEYMAN RA: Synthesis of high specific activity [3111-9-cis retinoic acid and its application for identify-ing retinoids with unusual binding properties. J. Med. Chem. (1994) 37:408–414.
   PubMed Web of Science ®Google Scholar
• BENEDETTI F, MILLFR W1-1, RIGAS J, TONG W, ULM E, TRUGLIA J, GILL G, WARRELL RP, Jr.: Initi21 clinical and pharmacokinetic study of 9-cis retinoic add. Proceed-ings of the American Association for Cancer Research (1995) 36:1445.
   Google Scholar
• MILLFR WIT, JAKUBOWSKI A, TONG WE, MIII.FR V, RIGAS JR, BENEDETTI F, GILL G, TRUGLIA J, ULM E, SHIRLEY M, WARRELL RP: 9-Cis retinoic acid reduces complete re- mission but does not reverse clinically acquired reti-noid resistance in acute promyelocytic leukemia. Blood (1995) 55:3021–3027.
   Google Scholar
• BOEHM MF, ZHANG L, BADEA BA, WHITE SK, MAIS DE, BERGER E, SUTO C, GOLDMAN ME, HEYMAN RA: Synthe-sis and structure activity relationships of novel retinoid
   Google Scholar
• X receptor selective retinoids. J. Med. Chem. (1994) 37:2930-2942. Describes the design and synthesis of the first RXR selective retinoid (LGD1069) to enter clinical trials.
   Google Scholar
• NAGY L, THOMAZY VA, SHIPLEY GL, FESUS L, LAMPH W, HEYMAN RA, CHANDRARATNA RAS, DAVIES PJA: Activa-tion of retinoid X receptors (RXR) induces apoptosis in 111.-60 cell lines. Mol. Cell. Biol. (1995) 15: In press.
   Google Scholar
• BOEHM MF, ZHANG L, ZHI L, MCCLURG MR, BERGER E, MAIS DE, SUTO CM, HEYMAN RA, NADZAN AM: Design and synthesis of potent retinoid X receptor selective ligands which induce apoptosis in leukemia cells./ Med. Chem. (1995) 38: In press.
   Google Scholar
• GOTTARDIS MM, LAMPH WW, SHALINSICY DR, MESICK CP, SESSIONS RB, SMITH RV, WRIGHT A, WELLSTEIN A: Anti-tumour efficacy of retinoids in primary human head and neck squamous cell carcinoma xenografts. Proceed-ings of the American Association for Cancer Research (1995) 36:3059.
   Google Scholar
• MB I FR VA, BENEDETTI FM, RIGAS JR, TONG WP, KRIS MG, GILL GM, TRUGLIA JA, ULM E, STRAUS D, WARRELL RP, Jr.: Initial clinical study of a retinoid X receptor (RXR) agonist Proceedings of the American Association for Cancer Research (1995) 36:1445.
   Google Scholar
• RIGAS JR, MID FR VA, LEVINE DM, VENKATRAMAN ES, GILL GM, TRUGLIA JA, WARRELL RP, Jr.: Lipoprotein altera-tions in patients treated with novel retinoids. Proceed-ings of the American Association for Cancer Research (1995) 36:3012.
   Google Scholar
• TOROK L, KADAR L, GEIGER JM: Acitretin treatment of severe psoriasis. Acta Derm. Venereol. (1989) 69(Suppl.):104–106.
   Google Scholar
• MORK NJ, KOLBENSTVEDT A, AUSTAD J: Efficacy and skeletal side-effects of two years' aciiretin treatment. Acta Derm. Venereol. Stockh. (1992) 72:445–448.
   PubMed Web of Science ®Google Scholar
• GOLLNICK H: Acitretin in psoriasis: An update. Retinoids: 10 years on. Saurat JH (Ed.). Karger, Basel, New York: 204–213.
   Google Scholar
• TURTON JA, WILLARS GB, HASELDON JN, WARD SJ, STEELE CE, HICKS RM: Comparative teratogenicity of nine reti-noids in the rat. Int. J. Exp. Pathol. (1992) 73:5551–5563.
   Google Scholar
• FRITSCH PO: Retinoids in psoriasis and disorders of keratinisation. J. Am. Acad. Dermatol. (1992) 27:S8–S14.
   PubMed Web of Science ®Google Scholar
• LAMBERT WE, MEYER E, DE-LEENBEER AP, DE BER-SAQUES J, KINT AH: Pharmacokinetics and drug inter-actions of etretinate and acitretin. J. Am. Acad. Dermatol, (1992) 27:S19–22.
   PubMed Web of Science ®Google Scholar
• BOUVY ML, STURKENBOOM MC, CORNEL MC, DE JONG VAN dEN BURG LT, STRICKER BH, WESSELING H: Acitretin (Neotigason). A review of phannacokinetics and tera-togenicity and hypothesis on metabolic pathways. Pharm. Weekbl. Sci. (1992) 14:33–37.
   Google Scholar
• MEYER E, DE-BERSAQUES J, LAMBERT WE, DE-LEENHEER AP, KINT AH: Skin, adipose tissue and plasma levels of Achretin with rare occurrence of esterified Acitretin during long-term treatment Acta. Derm. Venereol. Stockh. (1993) 73:113–115.
   PubMed Web of Science ®Google Scholar
• CHRISTOPHERSEN J, GEIGER JM, DANNESKIOLD SP, KRAGBALLE K, LARSON FG, LAURBERG G, SERUP J, THOM-SEN K: A double blind comparison of Acitretin and Etretinate in the treatment of Darier's disease. Acta Derm. Venereol. Stockh. (1992) 72:150–152.
   PubMed Web of Science ®Google Scholar
• LAUHARANTA J, GEIGER JM: A double blind comparison of Acitretin and Etretinate in combination with bath PUVA in the treatment of extensive psoriasis. Br. J. Dermatol. (1989) 121:107–112.
   PubMed Web of Science ®Google Scholar
• RUZICKA T, SOMMERBURG C, BRAUN FO, KOSTER W, LENGEN W, LENSING W, LETZEL H, MEIGEL WN, PAUL E, PRZYBILLAR B, STEINERT M, WINZER M, WISKEMANN A: Efficiency of acitretin in combination with UV-B in the treatment of severe psoriasis. Arch. Dermatol. (1990) 26:482–386.
   Google Scholar
• CORBEIL J, RAPAPORT E, RICHMOND DD, LOONEY DJ: Antiproliferative effect of retinoid compounds on Kaposrs sarcoma cells.J. Clin. Invest. (1994) 93: 1981-1986.
   Google Scholar
• SZMURLO A, MARCZAK M, JABLONSKA S, BOLLAG W: Antituntour action of retinoids: Inhibition of tumour cell line-induced angiogenesis and prevention of tu-mours in mice. Dermatology (1992) 184:116–119.
   PubMed Web of Science ®Google Scholar
• RUZICKA T, SOMMERBURG C, GOERZ G, KIND P, MENSING H: Treatment of cutaneous lupus erythemato-sus with Acitretin and hyroxychlorquine. Br. J. Derma-tot (1992) 127:513–518.
   PubMed Web of Science ®Google Scholar
• KULLAVANIJAYA P, KULTHANAN K: Clinical efficacy and side-effects of Acitretin on the disorders of keratinisa-tion: A one year study. J. Dermatol. (1993) 20:501–506.
   PubMedGoogle Scholar
• FUKASAWA H, IIJIMA T, KAGECHIKA H, HASHIMOTOT Y, SHUDO K: Expression of the ligand binding domain-containing region of retinoic acid receptors alpha, beta and gama in Escbericbia coil and evaluation of ligand-binding selectivity. Biol. Pharm. Bull. (1993) 16:343–348.
   PubMed Web of Science ®Google Scholar
• KOIZUMI H, SATO KC, KAZUKO C, OHICAWARA A: Effects of novel synthesised retinobenzoic acid (AM-80) on adenylate cydase and arac.hidonic acid release in pig epidermis. J. Dermatol. Sci. (1992) 3:97–102.
   Google Scholar
• OIKAWA T, OKAYASU I, ASHINO H, MORTTA I MUROTA 5, SHUDO K: Three novel synthetic retinoids, RE80, AM580, AM80, all exhibit anti-angiogenic activity in vivo. Eur. J. Pharmacol. (1993) 249:113–116.
   PubMed Web of Science ®Google Scholar
• PARTHASARATHY R, SACK PG, HARRIS D, BROCK H, MEHTA K: Interaction of liposome-assodated all-trans retinoic add with squainous carcinoma cells. Cancer Chemother. Pbarmacol. (1994) 34:527–534.
   PubMed Web of Science ®Google Scholar
• MEHTA K, SADEGHI T„MCQUEEN T, LOPEZ-BERESTEIN G: Liposomal encapsulation circumvents the hepatic clearance mechanisms of all-trans-retinoic acid. Leuke-mia Research (1994) 18:587–596.
   PubMed Web of Science ®Google Scholar
• MEHTA K, LOPEZ-BERESTEIN G, MCQUEEN T, ANDREEFF M, ESTEY E: Preclinical development of an intravenous all-trans-retinoic add formulation: Liposomal-RA. Pro-ceedings of the American Association for Cancer Research (1995) 36:1282.
   Google Scholar
• APFEL C, BAUER R, CRETTAZ M, FORNI L, KAMBER M, KAUFMANN F, LEMOTTE P, PTRSON W, KLAUS! M: A retinoic add receptor a antagonist selectively counter-acts retinoic acid effects. Proc. Natl. Acad. Sci. (1992) 89:7129–7133.
   PubMed Web of Science ®Google Scholar
• KANEKO S, KAGECHIKA H, KAWACHI E, HASHIMOTO Y, SHLTDO K: Retinoid antagonists. Med. Chem. Res. (1991) 1:220–225.
   Google Scholar
• ECKHARDT K, SCHMITT G: A retinok acid receptor a antagonist counteracts retinoid teratogenicity in vitro and reduced incidence and/or severity of malforma-tions in vivo. Tax. Lett. (1994) 70:299–308.
   PubMed Web of Science ®Google Scholar
• FENAUX P, CASTAIGNES S, DOMBERT H, ARCHIMBAUD E, DURARTE M, MOREL P, LAMY T, TILLY H, GUERCIA A, MALOISEL F, BORDESSOULLE D, SADOUN A, TIBERGIBEN P, FEGEUX N, DANIEL MT, CHOMIENNE C, DEGOS L: All-trans retioic acid followed by intensive chemother- apy gives a high complete remission rate and may prolong remissions in newly diagnosed acture promyelocytk leukemia: A pilot study on 26 cases. Blood (1992) 80:2176–2181.
   PubMed Web of Science ®Google Scholar
• FENAUX P, CHASTANG C, CHOMIENNE C, DEGOS L: Tretinoin with chemotherapy in newly diagnosed acute promyelocytic leukemia. Lancet (1994) 343:1033.
   PubMed Web of Science ®Google Scholar